| Testing peptides for activity against Leishmania |
2014 |
Leishmaniasis |
- Stanford University
- University of California San Diego (UCSD)
|
| Repurposing compounds for Neurocysticercosis drug discovery |
2014 |
Cysticercosis/Taeniasis |
- University of California San Diego (UCSD)
- University of California San Francisco (UCSF)
- National Institutes of Health (NIH)
|
| WIPO Fellowship - Research sabbatical in urogenital schistosomiasis |
2013 |
Schistosomiasis |
- Stanford University
- Theodor Bilharz Research Institute (TBRI)
|
| Using the Foldscope to diagnose Malaria |
2013 |
Malaria |
- Stanford University
- University of Lagos (Unilag)
|
| Screening Nature Bank Isolates for Activity Against Parasitic Helminths |
2014 |
Soil-transmitted helminthiasis (STH),Schistosomiasis |
- Griffith Institute for Drug Discovery (GRIDD)
- Swiss Tropical and Public Health Institute (Swiss TPH)
|
| Hosting and training in use of PCR to identify antimalarial resistance |
2014 |
Malaria |
- National Institute of Parasitic Diseases (NIPD)
- Chinese Center for Disease Control and Prevention
- University of Lagos (Unilag)
|
| Testing a diagnostic for Schistosoma japonicum against S. mansoni and S. haematobium |
2014 |
Schistosomiasis |
- National Institute of Parasitic Diseases (NIPD)
- Chinese Center for Disease Control and Prevention
- University of Ibadan
|
| Multiplexed RT-PCR for Diagnosing Febrile Illnesses in Cameroon |
2014 |
Malaria,Dengue |
- Stanford University
- Centre Pasteur du Cameroun (CPC)
|
| Hosting and assay optimization for undifferentiated febrile illnesses |
2014 |
Malaria,Dengue |
- Stanford University
- University of Lagos (Unilag)
|
| Repurposing Avermectins for Buruli Ulcer treatment |
2014 |
Buruli ulcer |
- Swiss Tropical and Public Health Institute (Swiss TPH)
- University of British Columbia (UBC)
|
| Concentrating soil-transmitted Helminths from soil and sewage samples |
2014 |
Soil-transmitted helminthiasis (STH) |
- McMaster University
- University of South Florida (USF)
|
| Assessing Host-Directed Activators for Liver-Stage Malaria |
2015 |
Malaria |
- Center for Infectious Disease Research (CIDR)
- Pfizer Inc.
|
| Virtual Screen of Phosphodiesterase (PDE) inhibitors against mycobacterium tuberculosis |
2014 |
Tuberculosis |
- Northeastern University
- Washington University in St. Louis (WUSTL)
- Center for World Health Medicine (Former Member)
|
| Screening Nature Bank Isolates for Activity Against Mycobacterium Tuberculosis |
2013 |
Tuberculosis |
- Griffith Institute for Drug Discovery (GRIDD)
- AstraZeneca (Former Member)
|
| Screening Cysteine Protease inhibitors for NTD drug discovery |
2012 |
Soil-transmitted helminthiasis (STH),Schistosomiasis,Malaria,Chagas disease,Human African trypanosomiasis (HAT) |
- University of California San Francisco (UCSF)
- AstraZeneca (Former Member)
|
| Screening Mycobacterium tuberculosis hits against Mycobacterium ulcerans |
2013 |
Buruli ulcer |
- Swiss Tropical and Public Health Institute (Swiss TPH)
- AstraZeneca (Former Member)
|
| Repurposing Cyp51 inhibitors for Chagas disease drug discovery |
2012 |
Chagas disease |
- University of California San Francisco (UCSF)
- AstraZeneca (Former Member)
|
| Data sharing to advance drug development for Kinetoplastid diseases and Malaria |
2015 |
Malaria,Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT) |
- Northeastern University
- Swiss Tropical and Public Health Institute (Swiss TPH)
- Drugs for Neglected Diseases initiative (DNDi)
|
| Re-purposing compounds for Chagas disease, Leishmaniasis, Lymphatic Filariasis, and Schistosomiasis drug discovery |
2015 |
Lymphatic filariasis,Schistosomiasis,Chagas disease,Leishmaniasis |
- University of California San Diego (UCSD)
- Eisai Co., Ltd.
|
| Repurposing nicotinic Acetylcholine receptor agonists for Hookworm |
2016 |
Soil-transmitted helminthiasis (STH) |
- Swiss Tropical and Public Health Institute (Swiss TPH)
- Pfizer Inc.
|
| Repurposing cicotinic Acetylcholine receptor agonists for STH |
2016 |
Soil-transmitted helminthiasis (STH) |
- Swiss Tropical and Public Health Institute (Swiss TPH)
- Johnson & Johnson
|
| Sharing of MetAP-1 Inhibitor data to inform Tuberculosis drug development strategies |
2012 |
Tuberculosis |
- GlaxoSmithKline (GSK)
- Center for World Health Medicine (Former Member)
|
| Advice on Phosphodiesterase (PDE) Inhibitor Optimization for HAT Drug Development |
2013 |
Human African trypanosomiasis (HAT) |
- Northeastern University
- Eisai Co., Ltd.
|
| Screening compounds for Malaria drug discovery |
2013 |
Malaria |
- University of Dundee
- Eisai Co., Ltd.
|
| Repurposing compounds for Malaria drug discovery |
2013 |
Malaria |
- University of Dundee
- Eisai Co., Ltd.
|
| Profiling of transmission-blocking compounds for Malaria treatment |
2012 |
Malaria |
- University of Washington (UW)
- GlaxoSmithKline (GSK)
|
| Screening compounds against the Wolbachia Endosymbiont of filarial nematodes |
2013 |
Lymphatic filariasis,Onchocerciasis |
- Liverpool School of Tropical Medicine (LSTM)
- AstraZeneca (Former Member)
|
| Repurposing GSK-3 Inhibitors for Kinetoplastids |
2012 |
Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT) |
- University of Dundee
- AstraZeneca (Former Member)
|
| Assessing Activity of Nucleoside Analogs against RNA and DNA Viruses |
2012 |
Dengue |
- Emory University
- National Institutes of Health (NIH)
|
| Expertise-sharing for Tuberculosis diagnostic development |
2014 |
Tuberculosis |
- California Institute of Technology (Caltech)
- PATH
|
| In Vitro ADME Support and Computational Modeling for HAT Drug Discovery |
2013 |
Human African trypanosomiasis (HAT) |
- Northeastern University
- AstraZeneca (Former Member)
|
| Providing Modipafant investigator’s brochure for Dengue drug development |
2013 |
Dengue |
- Pfizer Inc.
- 60P Pharmaceuticals (Former Member)
|
| Screening Polo-like Kinase Inhibitors for Schistosomiasis Drug Discovery |
2013 |
Schistosomiasis |
- University of California San Francisco (UCSF)
- GlaxoSmithKline (GSK)
|
| Designing optimized siRNAs for gene silencing in Schistosoma mansoni |
2013 |
Schistosomiasis |
- Aberystwyth University
- Alnylam (Former Member)
|
| Temperature control system to support PCR diagnostic for Malaria |
2014 |
Malaria |
- University of Calgary
- PATH
|
| NINA Heater for Reverse Transcription LAMP Assay to Detect Malaria |
2015 |
Malaria |
- Centre Pasteur du Cameroun (CPC)
- PATH
|
| Screening Xanthine analogs for Chagas disease drug discovery |
2015 |
Chagas disease |
- University of California San Diego (UCSD)
- GlaxoSmithKline (GSK)
|
| Repurposing compounds for Tuberculosis drug discovery |
2014 |
Tuberculosis |
- Infectious Disease Research Institute (IDRI)
- GlaxoSmithKline (GSK)
|
| Sharing anti-Malarial compounds to assess liver-stage Malaria screening system |
2014 |
Malaria |
- Massachusetts Institute of Technology (MIT)
- GlaxoSmithKline (GSK)
|
| Profiling Multi-Kinase Inhibitors for Malaria Drug Discovery |
2012 |
Malaria |
- University of Washington (UW)
- GlaxoSmithKline (GSK)
|
| Sharing of Kinase inhibitors for testing against liver stage Malaria parasites |
2014 |
Malaria |
- National Institute of Immunology (NII)
- GlaxoSmithKline (GSK)
|
| WIPO Fellowship - Hosting and training on malaria diagnostics development |
2013 |
Malaria |
- University of Lagos (Unilag)
- Novartis AG
|
| Testing JAK-3 Kinase inhibitor in cerebral Malaria animal model |
2013 |
Malaria |
- McGill University
- Pfizer Inc.
|
| Formulation advice for a topically-administered anti-Leishmania compound |
2013 |
Leishmaniasis |
- Stanford University
- AstraZeneca (Former Member)
|
| Repurposing preclinical and clinical candidates for Malaria |
2012 |
Malaria |
- Liverpool School of Tropical Medicine (LSTM)
- AstraZeneca (Former Member)
|
| Using C. Elegans to search for anti-helminth compounds |
2013 |
Soil-transmitted helminthiasis (STH) |
- McGill University
- AstraZeneca (Former Member)
|
| Compound Repurposing for Human African Trypanosomiasis Drug Discovery |
2014 |
Human African trypanosomiasis (HAT) |
- Center for Infectious Disease Research (CIDR)
- GlaxoSmithKline (GSK)
|
| Using C. Elegans mutants to elucidate Anthelmintic compounds’ mechanisms of action |
2013 |
Soil-transmitted helminthiasis (STH),Onchocerciasis |
- McGill University
- Drugs for Neglected Diseases initiative (DNDi)
- AstraZeneca (Former Member)
|
| Screening Boron-based compounds against Mycobacterium tuberculosis drug targets |
2012 |
Tuberculosis |
- AstraZeneca (Former Member)
- Anacor (Former member)
|
| Screening inhibitors against Onchocerca microfilariae and macrofilariae |
2014 |
Onchocerciasis |
- Aberystwyth University
- University of Buea
|
| siRNAs targeting a hepatocyte receptor on P. falciparum invasion of hepatocytes in vivo |
2016 |
Malaria |
- Center for Infectious Disease Research (CIDR)
- Alnylam (Former Member)
|
| Gene validation studies via RNAi for drug discovery efforts against Schistosoma mansoni |
2017 |
Schistosomiasis |
- Oswaldo Cruz Foundation (Fiocruz)
- Alnylam (Former Member)
|
| Optimized siRNAs to assess regulation of host hepatocyte genes during liver-stage malaria |
2014 |
Malaria |
- Northeastern University
- National Institute of Immunology (NII)
- Alnylam (Former Member)
|
| Optimized siRNAs against a host protein expressed in macrophages during M. Tuberculosis infection |
2014 |
Tuberculosis |
- Tulane University
- Alnylam (Former Member)
|
| Knowledge, data, and structures of inhibitors for product development against Shigella |
2012 |
Tuberculosis |
- AstraZeneca (Former Member)
- Anacor (Former member)
|
| Express and purify a recombinant Schistosoma protein to assess in vitro immune response to this protein in human cells |
2015 |
Schistosomiasis |
- Biomedical Research Institute (BRI)
- University Cheikh Anta Diop of Dakar (UCAD)
|
| Computational and predictive chemistry know-how and support to improve compound characteristics for tuberculosis drug candidates |
2012 |
Tuberculosis |
- AstraZeneca (Former Member)
- iThemba (Former member)
|
| Share of Genomic DNA from S. mansoni and parasite’s intermediate snail host, B. pfeifferi |
2016 |
Schistosomiasis |
- Biomedical Research Institute (BRI)
- Nigerian Institute of Medical Research (NIMR)
|
| Share of natural product extracts to screen against Plasmodium parasites in vitro. |
2016 |
Malaria |
- Centre Pasteur du Cameroun (CPC)
- Nigerian Institute of Medical Research (NIMR)
|
| Knowledge exchange on parameters to consider during adjuvant design |
2013 |
Unknown disease |
- Infectious Disease Research Institute (IDRI)
- Eisai Co., Ltd.
|
| Share of phosphodiesterase (PDE) V inhibitors and calcium channel blockers to screen the compounds for activity against intracellular M. tuberculosis |
2018 |
Tuberculosis |
- Infectious Disease Research Institute (IDRI)
- Eisai Co., Ltd.
|
| Knowledge exchange on formulation of anti-fungal compound |
2013 |
Unknown disease |
- Eisai Co., Ltd.
- University of Kansas
|
| Share of inhibitors to test against cerebral Malaria |
2014 |
Malaria |
- Liverpool School of Tropical Medicine (LSTM)
- Eisai Co., Ltd.
|
| Share classes of inhibitors including kinase inhibitors and calcium channel blockers to screen for activity against Onchocerca adult worm |
2018 |
Onchocerciasis |
- University of Buea
- Eisai Co., Ltd.
|
| Share of inhibitors to screen against Leishmania, T. cruzi, S. mansoni, and Brugia |
2015 |
Chagas disease,Leishmaniasis |
- University of California San Diego (UCSD)
- Eisai Co., Ltd.
|
| Share of two targeted sets of inhibitors to screen against S. mansoni |
2017 |
Schistosomiasis |
- University of California San Diego (UCSD)
- Eisai Co., Ltd.
|
| Share of targeted set of inhibitors and their structures to test against Leishmania spp. and T. cruzi |
2017 |
Chagas disease,Leishmaniasis |
- University of California San Diego (UCSD)
- Eisai Co., Ltd.
|
| Advice regarding a Polio diagnostic |
2014 |
Unknown disease |
- Emory University
- California Institute of Technology (Caltech)
|
| Share of in vivo data to license a virus strain and provide its animal model set up guidance |
2014 |
Unknown disease |
- Emory University
- Kineta (Former member)
|
| Measure the plasmablast response induced in human subjects following administration of two candidate dengue vaccines |
2014 |
Dengue |
- Emory University
- Walter Reed Army Institute of Research (WRAIR)
- GlaxoSmithKline (GSK)
|
| Share of resistant TB strains to see efficiency of a promising drug |
2017 |
Tuberculosis |
- Institut Pasteur Korea
- Foundation for Innovative New Diagnostics (FIND)
|
| Share of targeted set of compounds from its TCAKS to assess their effects on T. cruzi |
2015 |
Chagas disease |
- Oswaldo Cruz Foundation (Fiocruz)
- GlaxoSmithKline (GSK)
|
| Share of kinase inhibitors to study M. tuberculosis metabolic pathways |
2013 |
Malaria |
- National Institute of Immunology (NII)
- GlaxoSmithKline (GSK)
|
| Share of set of kinase inhibitors to screen against liver-stage malaria parasites |
2014 |
Malaria |
- National Institute of Immunology (NII)
- GlaxoSmithKline (GSK)
|
| Share of set of compounds with different anti-malarial properties to test effects on erythrocyte deformability during Plasmodium infection |
2015 |
Malaria |
- University of British Columbia (UBC)
- GlaxoSmithKline (GSK)
|
| Share of small molecules which previously demonstrated to have promising activity against M. tuberculosis-infected macrophages in vitro |
2017 |
Tuberculosis |
- University of California
- Berkeley (UCB)
- GlaxoSmithKline (GSK)
|
| Expertise and advice to improve the solubility and bioavailability and anti-tuberculosis coumponds |
2013 |
Tuberculosis |
- Infectious Disease Research Institute (IDRI)
- South African Medical Research Council (SAMRC)
|
| Share of Jump-stARter library to screen against Mycobacterium tuberculosis in vitro under conditions that mimic important aspects of human pathogenesis |
2017 |
Tuberculosis |
- National Institutes of Health (NIH)
- Johnson & Johnson
|
| Share of Jump-stARter library to screen the library against C. elegans to identify inhibitors of a unique metabolic pathway found in parasitic worms. |
2017 |
Soil-transmitted helminthiasis (STH) |
- University of Toronto (U of T)
- Johnson & Johnson
|
| Share of Jump-stARter library to screen against P. falciparum in vitro |
2016 |
Malaria |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- Johnson & Johnson
|
| Share of Jump-stARter library to screen against a Mycobacterium tuberculosis enzyme |
2017 |
Tuberculosis |
- Washington University in St. Louis (WUSTL)
- Johnson & Johnson
|
| Exploration of grant opportunities, exchange between students, collaborative lab projects |
2013 |
Unknown disease |
- Northeastern University
- Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
|
| Share of stool samples to support the researchers’ helminth diagnostic product development and testing |
2012 |
Soil-transmitted helminthiasis (STH) |
- Stanford University
- Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
|
| Develop formulations of antiviral |
2014 |
Dengue |
- University of Kansas
- Kineta (Former member)
|
| Share of stool and plasma samples from Trichuris-infected children in Ecuador |
2014 |
Soil-transmitted helminthiasis (STH) |
- University of California San Francisco (UCSF)
- Liverpool School of Tropical Medicine (LSTM)
|
| Share of frozen cell extracts of Cryptosporidium infected cells to identify potential antigens for use in a vaccine |
2014 |
Unknown disease |
- McGill University
- University of British Columbia (UBC)
|
| Share of frozen cell extracts of T. cruzi infected cell to identify potential antigens for use in a vaccine |
2014 |
Chagas disease |
- McGill University
- University of British Columbia (UBC)
|
| Microfluidic diagnostic to detect bacteria in banked milk |
2015 |
Unknown disease |
|
| Library of phosphoinositide-3-kinase (PI3K) inhibitors to screen against various NTDs |
2017 |
Chagas disease,Human African trypanosomiasis (HAT) |
- University of California San Diego (UCSD)
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
| Highly potent Hsp90 inhibitors to screen against Onchocerca worms |
2015 |
Onchocerciasis |
- University of Buea
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
| Membrane-bound protein purification expertise for Tuberculosis |
2013 |
Tuberculosis |
- Emory University
- MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
|
| HMG-CoA reductase inhibitors (statins) to screen against schistosomal worms |
2012 |
Schistosomiasis |
- Center for Infectious Disease Research (CIDR)
- University of California San Diego (UCSD)
- University of California San Francisco (UCSF)
- MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
|
| Set of compounds to screen against Plasmodium |
2014 |
Malaria |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
|
| Natural product extracts to screen against M. tuberculosis |
2013 |
Tuberculosis |
- Infectious Disease Research Institute (IDRI)
- National Institutes of Health (NIH)
|
| Natural products to test against kinetoplastids |
2015 |
Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT) |
- Institut Pasteur Korea
- National Institutes of Health (NIH)
|
| Use of preclinical services program to increase thermostability of investigational rabies vaccine |
2015 |
Rabies |
- Institut Pasteur de Tunis
- National Institutes of Health (NIH)
|
| K13 gene of Plasmodium falciparum parasites found within malaria patient blood samples |
2017 |
Malaria |
- Centre Pasteur du Cameroun (CPC)
- National Institute of Parasitic Diseases (NIPD)
- Chinese Center for Disease Control and Prevention
|
| Sequence of K13 gene of a set of malaria parasites obtained from Senegalese malaria patients |
2016 |
Malaria |
- University Cheikh Anta Diop of Dakar (UCAD)
- National Institute of Parasitic Diseases (NIPD)
- Chinese Center for Disease Control and Prevention
|
| Identify potential Schistosoma mansoni and S. haematobium antigens for rapid diagnostic |
2016 |
Schistosomiasis |
- National Institute of Parasitic Diseases (NIPD)
- Chinese Center for Disease Control and Prevention
- University of Ibadan
|
| Polyclonal anti-dengue antibody |
2013 |
Dengue |
- McMaster University
- Novartis AG
|
| Co-development of a novel onchocerciasis diagnostic |
2012 |
Onchocerciasis |
- Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
- PATH
|
| Compounds to evaluate in a rat diarrhea model |
2013 |
Unknown disease |
- Pfizer Inc.
- Center for World Health Medicine (Former Member)
|
| Documentation and expertise on diarrheal diseases |
2013 |
Unknown disease |
|
| Inhibitor to test in an animal model of diarrhea |
2014 |
Unknown disease |
- Pfizer Inc.
- PATH
- University of Vermont (UVM)
|
| Compounds to evaluate in a rat diarrhea model |
2013 |
Unknown disease |
- Sanofi (Former Member)
- Center for World Health Medicine (Former Member)
|
| DNA and primers to test in a microfluidics instrument |
2014 |
Dengue |
- Stanford University
- California Institute of Technology (Caltech)
|
| Paper microscopes used to test samples for helminth eggs |
2016 |
Soil-transmitted helminthiasis (STH) |
- Stanford University
- University of South Florida (USF)
|
| Use of microneedle patch technology to administer a protein antigen-based, transmission-blocking malaria vaccine |
2017 |
Malaria |
- National Institutes of Health (NIH)
- Takeda Pharmaceutical Company Limited
|
| Targeted set of compounds to screen against M. tuberculosis residing within macrophages |
2016 |
Tuberculosis |
- University of British Columbia (UBC)
- Takeda Pharmaceutical Company Limited
|
| Targeted set of compounds to screen against Schistosoma mansoni in vitro |
2016 |
Schistosomiasis |
- University of California San Diego (UCSD)
- Takeda Pharmaceutical Company Limited
|
| Set of preclinical/clinical-stage compounds to screen against B. pahangi |
2017 |
Lymphatic filariasis |
- University of California San Francisco (UCSF)
- Takeda Pharmaceutical Company Limited
|
| Share of blood samples from malaria patients with varying levels of parasitemia for diagnostic development |
2015 |
Malaria |
- McGill University
- University of Lagos (Unilag)
|
| Dried blood spot sampling (DBSS) and next generation sequencing of Plasmodium falciparum in malaria patients in Nigeria |
2014 |
Malaria |
- University of Lagos (Unilag)
- Novartis AG
|
| Antibodies against Chagas disease host biomarkers for diagnostic development |
2014 |
Chagas disease |
- McGill University
- University of British Columbia (UBC)
|
| Activity-guided fractionation on natural product extracts that have anti-onchocercal activities. |
2014 |
Onchocerciasis |
- University of British Columbia (UBC)
- University of Buea
|
| Elucidate the structures of natural products that previously demonstrated to have anti-malarial or anti-tuberculosis activities |
2014 |
Malaria,Tuberculosis |
- University of British Columbia (UBC)
- University of Ibadan
|
| Antibody against a human host protein to examine the effect of reducing the level of the host protein on the severity of malaria |
2015 |
Malaria |
- University of British Columbia (UBC)
- University of Lagos (Unilag)
|
| Identification of biomarkers for a malaria diagnostic |
2015 |
Malaria |
- University of British Columbia (UBC)
- University of Lagos (Unilag)
|
| Antibodies against the proteins assessed for their ability to block P. vivax entry into red blood cells |
2015 |
Malaria |
- University of British Columbia (UBC)
- Walter and Eliza Hall Institute of Medical Research (WEHI)
|
| Set of T. cruzi antigens to incorporate into a silicon chip-based Chagas disease diagnostic |
2015 |
Chagas disease |
- University of California San Diego (UCSD)
- University of Washington (UW)
|
| Collaboration to assess the efficacy of tuberculosis drugs using different delivery strategies |
2014 |
Tuberculosis |
- Emory University
- Northeastern University
- University of Mauritius
|
| Analyze the potential of Cameroonian fungi and medicinal plants for drugs development |
2017 |
Buruli ulcer,Schistosomiasis,Leishmaniasis,Human African trypanosomiasis (HAT) |
- University of South Florida (USF)
- University of Yaoundé I
|
| Co-development and implementation of a bioinformatics course |
2015 |
Malaria,Tuberculosis |
- University of Washington (UW)
- Noguchi Memorial Institute for Medical Research (NMIMR)
|
| Analyze of sequence variation of a P. falciparum red blood cell-binding protein within a set of malaria patient samples |
2015 |
Malaria |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- University Cheikh Anta Diop of Dakar (UCAD)
|
| Inhibitors against Fasciola |
2014 |
Onchocerciasis |
- Aberystwyth University
- University of Buea
|
| Activity against S. mansoni and S. haematobium or their intermediate snail hosts. |
2018 |
Schistosomiasis |
- Griffith Institute for Drug Discovery (GRIDD)
- University of Ibadan
|
| Developing an antibody-based diagnostic device with the ability to detect adult stage O. volvulus. |
2018 |
Onchocerciasis |
- University of British Columbia (UBC)
- University of Buea
|
| In vitro test of inhibitors for anti-parasitic drug discovery |
2018 |
Leishmaniasis |
- Center for Infectious Disease Research (CIDR)
- Takeda Pharmaceutical Company Limited
|
| Synthesize an inhibitor against malaria parasites |
2014 |
Malaria |
- McGill University
- Northeastern University
|
| Use of phage-display technology to develop new antibodies against chagas disease host biomarkers |
2014 |
Chagas disease |
- McGill University
- University of British Columbia (UBC)
|
| Identification of hit inhibitors of critical parasitic metabolic pathways to develop drugs against HAT, leishmaniasis, and malaria |
2018 |
Malaria,Leishmaniasis,Human African trypanosomiasis (HAT) |
- University of Yaoundé I
- Johnson & Johnson
|
| Jump-stARter library to screen against intracellular M. tuberculosis and Leishmania parasites |
2017 |
Leishmaniasis,Tuberculosis |
- Infectious Disease Research Institute (IDRI)
- Johnson & Johnson
|
| Screen compounds against Onchocerca volvulus to identify potential drug candidates |
2018 |
Onchocerciasis |
- Monash University
- University of Melbourne
- University of Buea
|
| WIPO Fellowship - Research in Onchocerciasis (river blindness) |
2013 |
Onchocerciasis |
- University of Buea
- Novartis AG
|
| WIPO Fellowship - Screening natural products sourced in Ghana against various parasites responsible for NTDs |
2013 |
Lymphatic filariasis,Schistosomiasis,Chagas disease,Human African trypanosomiasis (HAT) |
- University of California San Francisco (UCSF)
- University of Ghana
|
| WIPO Fellowship - Screening plant extracts and compounds against schistosomiasis and other parasites |
2015 |
Schistosomiasis,Leishmaniasis,Human African trypanosomiasis (HAT) |
- University of California San Diego (UCSD)
- University of Ghana
|
| WIPO Fellowship - Setting up different assays to find the best drug to treat tuberculosis |
2013 |
Tuberculosis |
- AstraZeneca (Former Member)
- South African Medical Research Council (SAMRC)
|
| WIPO Fellowship - Probing the ubiquitination system as a target for developing new anti-malarials |
2017 |
Malaria |
- University of Melbourne
- International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
|
| WIPO Fellowship - Molecular surveillance and the development of genomic tools for malaria control |
2017 |
Malaria |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- Papua New Guinea Institute of Medical Research (PNGIMR)
|
| WIPO Fellowship - Training in malaria drug discovery with emphasis on natural product drug discovery |
2017 |
Malaria |
- Griffith Institute for Drug Discovery (GRIDD)
- International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
|
| WIPO Fellowship - Testing the feasibility to use IR spectroscopy for the detection of antimalarial resistance |
2018 |
Malaria |
- Monash University
- National Institute for Medical Research (NIMR)
|
| WIPO Fellowship - Identifying genetic biomarkers for disease susceptibility |
2018 |
Dengue |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- Eijkman Institute for Molecular Biology (EIMB)
|
| WIPO Fellowship - Using system-wide approach to investigate the mechanisms of naturally acquired immunity against Malaria |
2018 |
Malaria |
- Monash University
- Kenya Medical Research Institute (KEMRI)
|
| WIPO Fellowship - Identifying candidate targets for naturally acquired immunity for the design of novel anti-malarial vaccines |
2018 |
Malaria |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- Eijkman Institute for Molecular Biology (EIMB)
|
| WIPO Fellowship - Identification of functional blocking antibody to inhibit the entry of the malarial parasite in red blood cells |
2018 |
Malaria |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- Bandung Institute of Technology (ITB)
|
| WIPO Fellowship - Assessing the immunological correlates possibly associated with extrapulmonary dissemination of mycobacterium tuberculosis (Mtb) |
2018 |
Tuberculosis |
- Walter and Eliza Hall Institute of Medical Research (WEHI)
- Institut Pasteur de Madagascar (IPM)
|
| Assay Support for Testing Lead Compounds for Activity Against a Specific Mycobacterium tuberculosis Target |
2018 |
Tuberculosis |
- The George Washington University (GW)
- MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
|
| Screening Dihydrofolate Reductase (DHFR) Inhibitors and Potassium Channel Blockers for HAT, Leishmaniasis, and Malaria Drug Discovery |
2019 |
Malaria,Leishmaniasis,Human African trypanosomiasis (HAT) |
- University of Yaoundé I
- Eisai Co., Ltd.
|
| Screening the Jump-stARter Library for Antimalarial Drug Discovery |
2018 |
Malaria |
- Washington University in St. Louis (WUSTL)
- Johnson & Johnson
|
| Ampli Blocks for Onchocerciasis Disgnostic Development |
2018 |
Onchocerciasis |
- Massachusetts Institute of Technology (MIT)
- University of Buea
|
| Sharing of Artefenomel-like Trioxolane Analogs for Microsome Stability Testing |
2018 |
Malaria |
- University of California San Francisco (UCSF)
- Medicines for Malaria Venture (MMV)
|
| Expertise Sharing for Alternate Administration of Antimalarial Candidate |
2018 |
Malaria |
- The George Washington University (GW)
- Washington University in St. Louis (WUSTL)
- Pfizer Inc.
|
| Identification of New Inhibitors of Trypanosoma cruzi Enzymes |
2019 |
Chagas disease |
- Brazilian Biosciences National Laboratory (LNBio)
- Novartis AG
|
| Evaluation of Bactericidal Activity of TB47 Against Clinical M. Ulcerans Strains In Vitro |
2019 |
Buruli ulcer |
- Guangzhou Institutes of Biomedicine and Health (GIBH)
- Chinese Academy of Sciences
- University of Yaoundé I
|
| Sharing Compounds for Leishmaniasis Drug Discovery |
2019 |
Leishmaniasis |
- Eisai Co., Ltd.
- University of Texas (UT) Southwestern Medical Center
|
| Screening TCAMS Library for Antimalarial Drug Discovery |
2019 |
Malaria |
- Washington University in St. Louis (WUSTL)
- GlaxoSmithKline (GSK)
|
| Generating a Codon-Optimized Gene Construct to Aid SSGCID in their Structural Elucidation Efforts |
2019 |
Schistosomiasis |
- MSD (Known as Merck & Co. Inc. in the United States of America and Canada)
- Seattle Children's Research Institute (SCRI)
|
| Screening of Merck KGaA, Darmstadt, Germany’s Mini Library for Buruli Ulcer Drug Discovery |
2019 |
Buruli ulcer |
- University of Yaoundé I
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
| Screening of Merck KGaA, Darmstadt, Germany’s Mini Library for Chagas Disease, Human African Trypanosomiasis, and Leishmaniasis Drug Discovery |
2020 |
Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT) |
- Griffith Institute for Drug Discovery (GRIDD)
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
| Screening of Phenotypic Library for Antimalarial Drug Discovery |
2019 |
Malaria |
- Johnson & Johnson
- Usmanu Danfodiyo University
- Sokoto (UDUS)
|
| Screening Jump-stARter Library Against Various Nematodes |
2019 |
Soil-transmitted helminthiasis (STH) |
- University of Melbourne
- Johnson & Johnson
|
| Schistosomiasis Biomarker Validation and Proteomic Support |
2020 |
Schistosomiasis |
- University of British Columbia (UBC)
- University of Ibadan
|
| Sharing of Phenotypic Library and Specific Compound Class For Snakebite Envenoming Drug Discovery |
2019 |
Snakebite |
- Liverpool School of Tropical Medicine (LSTM)
- Johnson & Johnson
|
| Screening Jump-stARter Library for Leishmaniasis Drug Discovery |
2020 |
Leishmaniasis |
- University of Washington (UW)
- Johnson & Johnson
- Seattle Children's Research Institute (SCRI)
|
| Expression of Trypanosoma cruzi Topoisomerase II |
2020 |
Chagas disease |
- Oswaldo Cruz Foundation (Fiocruz)
- Seattle Children's Research Institute (SCRI)
|
| Screening of Merck KGaA Mini Library for Leishmaniasis and Amoebiasis Drug Discovery |
2020 |
Other - HIV, Chikungunya, Influenza, Zika,Leishmaniasis |
- University of Yaoundé I
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
| Screening Ghanaian Natural Product Extracts for Human African Trypanosomiasis (HAT) and Schistosomiasis Drug Discovery |
2020 |
Schistosomiasis,Human African trypanosomiasis (HAT) |
- University of California San Diego (UCSD)
- Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
|
| Sharing Potassium Channel Blockers for Human African Trypanosomiasis, Leishmaniasis, and Malaria Drug Discovery |
2021 |
Malaria,Leishmaniasis,Human African trypanosomiasis (HAT) |
- University of Yaoundé I
- Pfizer Inc.
|
| Screening Natural Products For Schistosomiasis Drug Discovery |
2021 |
Schistosomiasis |
- University of California San Diego (UCSD)
- University of Zambia
|
| Crystallization of Potential Drug Targets for Kinetoplastid Diseases |
2021 |
Chagas disease,Leishmaniasis,Human African trypanosomiasis (HAT) |
- Seattle Children's Research Institute (SCRI)
- Institut Pasteur de Montevideo
|
| Screening Pfizer Compounds for Antimalarial Drug Discovery |
2021 |
Malaria |
- Pfizer Inc.
- University of Tokyo
|
| Screening of Open Global Health Library for Schistosomiasis Drug Discovery |
2021 |
Schistosomiasis |
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
- AHMADU BELLO UNIVERSITY ZARIA
|
| Screening of African Natural Product Extracts for Antischistosomal Activity |
2021 |
Schistosomiasis |
- Swiss Tropical and Public Health Institute (Swiss TPH)
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
| Screening of Open Global Health Library for Dengue Drug Discovery |
2021 |
Dengue |
- Eijkman Institute for Molecular Biology (EIMB)
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
| Screening of Open Global Health Library for Snakebite Drug Discovery |
2021 |
Snakebite |
- Liverpool School of Tropical Medicine (LSTM)
- Merck KGaA (Known as Merck KGaA, Darmstadt, Germany in the United States of America and Canada)
|
